Doser
Develops desktop 3D printers using semi-solid extrusion (SSE) for pharmacists to produce personalized medication on demand.
- CEO / Founder
- Arjan van Unen
- Team Size
- 11-50
- Stage
- Commercial
- Total Funding
- €500K
- Latest Round
- Seed
- Key Investors
- Libertatis Ergo Holding (LEH), AntiJanteLoven Capital, PLNT, unlock_
Technology & Products
Key Products
DoseRx1
Technological Advantage
Covers ~80% of oral medications and allows customization of dosage, size, shape, color, taste, and texture in a desktop format.
Differentiation
Value Proposition
Enables on-demand production of tailor-made pills adjusted for age, weight, and condition, reducing side effects and addressing orphan drugs with a throughput of 100-1000 doses/hour.
How They Differentiate
Positioned as the 'Nespresso machine for pills,' offering a desktop solution for pharmacy-level compounding vs industrial manufacturing.
Market & Competition
Target Customers
Pharmacists, hospitals, and researchers
Industry Verticals
Medical; Pharmaceutical Compounding; Precision Healthcare
Competitors
FabRx, CurifyLabs, CraftHealth
Growth & Milestones
Growth Metrics
Prints 100-1000 doses/hour; enables >80% of oral medications; goal to increase personalized treatments from <3% to 10% of patients in 10 years.
Major Milestones
First clinical study at Leiden University (2021); DoseRx1 launch at CES 2024; Received CES 2024 Innovation Award
Notable Customers
Leiden University Medical Center (LUMC)